Effectiveness of post-trastuzumab deruxtecan treatments and incidence of interstitial lung disease in HER2-positive metastatic breast cancer: a real-world, observational cohort study.

ABSTRACT:

Background

Trastuzumab deruxtecan (T-DXd) is recommended in the second-line or later setting for patients with human epidermal growth factor receptor 2 (HER2)-positive recurrent or metastatic breast cancer (mBC). However, clinical evidence for optimal post-T-DXd treatment is lacking. The EN-SEMBLE study examined the distribution of post-T-DXd treatment regimens, their effectiveness, and the incidence of interstitial lung disease (ILD) in the real-world setting.

Patients and methods

EN-SEMBLE was a real-world, observational, cohort study conducted nationwide in Japan. Patients with HER2-positive mBC who received T-DXd between 25 May 2020 and 30 November 2021 and started another treatment regimen after T-DXd discontinuation were eligible for inclusion. Study outcomes included

SUBMITTER: Nozawa K 

PROVIDER: S-EPMC12314378 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature